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Abstract  The  resurgence  of  tuberculosis  and  the  appearance  of  multidrug-resistant  strains
of Mycobacterium  tuberculosis  are  due  to  several  different  factors.  Principal  among  these
is the  worldwide  prevalence  of  autoimmune  deﬁciency  syndrome  (AIDS),  coupled  with  mis-
directed therapeutic  practices  and  patient  non-compliance,  the  latter  being  derived  from
the undesirable  side  effects  of  anti-tuberculosis  drugs.  Aside  from  AIDS,  other  diseases  or
immunosuppressive  disorders  have  been  associated  with  this  new  phase  of  tuberculosis  infec-
tion. Metabolic  disorders  such  as  diabetes,  which  is  closely  associated  with  obesity,  are  among
the most  important  immunosuppressive  diseases.  Diabetes  is  a  major  public  health  problem  in
Mexico, a  country  that  leads  the  world  in  the  incidence  of  childhood  obesity.
The aim  of  this  study  is  to  analyse  the  different  factors  involved  in  this  phenomenon  and  to
give a  clear,  comprehensive  picture  of  the  problem  of  tuberculosis  resurgence  and  its  correlation
with diabetes  and  metabolic  syndrome.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
S.A. All  rights  reserved.
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Resumen  El  resurgimiento  de  la  tuberculosis  y  la  aparición  de  nuevas  cepas  de  Mycobacterias
poliresistentes  tienen  un  origen  multifactorial.  Entre  las  principales  causas  involucradas  seSíndrome  metabólico;
México
encuentran  el  alto  número  de  casos  de  pacientes  con  Síndrome  de  Inmunodeﬁciencia  Adquirida
(SIDA) a  nivel  mundial,  así  como  incorrectas  prácticas  terapeúticas  y  la  falta  de  apego  a  ellas
por parte  del  paciente,  esta  última  derivada  de  los  indeseables  efectos  secundarios  de  los
antituberculosos.  Independientemente  de  los  casos  de  SIDA,  otras  enfermedades  o  condiciones
inmunosupresoras  han  sido  de  igual  forma  relacionadas  con  esta  nueva  fase  de  la  tuberculosis.
Dentro de  las  principales  enfermedades  que  propician  un  estado  de  inmunodepresión  en  el∗ Corresponding author at: Facultad de Ciencias de la Salud, Universidad Anáhuac. Av. Universidad Anáhuac, #46, Col. Lomas Anáhuac,
C.P. 52787, Huixquilucan, Estado de México, México.
E-mail address: rosalino.vazquez@anahuac.mx (R. Vázquez-López).
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paciente  se  encuentran  las  enfermedades  metabólicas  como  la  diabetes,  esta  condición  está
estrechamente  relacionada  con  la  obesidad,  problema  de  salud  pública  del  cual  en  su  forma
infantil México  ocupa  el  primer  lugar  a  nivel  mundial.  La  presente  investigación  documental
tiene como  objetivo  aportar  elementos  de  análisis  que  nos  acerquen  a  un  entendimiento  integral
de la  problemática  del  resurgimiento  de  la  tuberculosis  y  su  correlación  con  diabetes  y  síndrome
metabólico.
© 2015  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
S.A. Todos  los  derechos  reservados.
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etabolic  syndrome  is  a  cluster  of  risk  factors  that  include
yperglycaemia/insulin  resistance,  high  blood  triglycerides,
ow  levels  of  HDL  cholesterol,  abdominal  or  visceral  obesity,
nd  arterial  hypertension.1,2 Diagnosis  of  metabolic  syn-
rome  is  important,  as  it  can  identify  patients  at  high  risk  for
ardiovascular  disease  and  type  2  diabetes  mellitus  (DM).2
pproximately  1  in  every  4--6  adults  develops  metabolic  syn-
rome,  and  it  affects  around  30%  of  individuals  over  50  years
n  Europe,  and  40%  in  the  USA.3,4
Tuberculosis  (TB)  is  the  most  devastating  infectious  dis-
ase  known  to  man,  and  was  the  primary  cause  of  death
n  Europe  in  the  19th  century.5 Incidence  of  this  dis-
ase  is  currently  on  the  rise  due  to  an  increase  in  the
umber  of  patients  with  immune  deﬁciency  secondary  to
uman  immunodeﬁciency  virus  infection  (HIV),6 which  in
urn  increases  the  risk  of  a  resurgence  of  Mycobacterium
uberculosis  infection.6
In  2008,  14,986  new  cases  of  tuberculosis  were  reported
n  Mexico,  with  4896  deaths  from  the  disease.7 The  rela-
ionship  between  diabetes  and  tuberculosis  has  been  known
or  decades;  a  study  published  by  Root  as  far  back  as  1934
ound  that  nearly  85%  of  the  245  study  patients  with  both
iseases  had  developed  tuberculosis  after  being  diagnosed
ith  diabetes  mellitus.7
etabolic syndrome and diabetes mellitus
he  World  Health  Organisation  (WHO),  the  National  Choles-
erol  Education  Programme  Adult  Treatment  Panel  III  (ATP
II),  the  International  Diabetes  Federation  (IDF),  and  the
merican  Heart  Association/National  Heart,  Lung  and  Blood
nstitute  (AHA/NHLBI)  have  deﬁned  a  number  of  parameters
ssociated  with  metabolic  syndrome  (Table  1).
According  to  the  WHO,  insulin  resistance  is  the  primary
isk  factor  and  is  a  pre-requisite  for  a  deﬁnitive  diagnosis  of
etabolic  syndrome.8,9 For  the  ATP  III,  however,  diagnosis  is
onﬁrmed  when  any  3  of  the  5  risk  factors  are  present.9--11
he  IDF  made  abdominal  obesity  a  prerequisite  for  diagnosis
f  metabolic  syndrome,9,12 while  the  AHA/NHLBI  modiﬁed
he  ATP  III  criteria  and  does  not  require  any  particular  factor
s  a  prerequisite  for  diagnosis.9,13,14
Elevated  fasting  glucose,  one  of  the  conditions  included
n  metabolic  syndrome,  was  long  thought  to  be  the  pri-
ary  predictor  of  diabetes.  However,  Lorenzo  et  al.  showed
d
c
3hat  taking  all  metabolic  syndrome  factors  together  had  a
uperior  predictive  value  for  the  development  of  diabetes.
ord,  Li  and  Sattar,  meanwhile,  concluded  that  diagnosis  of
etabolic  syndrome  was  a  more  accurate  predictor  of  devel-
pment  of  diabetes  than  of  cardiovascular  disease.15,16 The
HO  has  described  DM  as  an  epidemic  that  primarily  affects
eveloping  countries.  Diabetes  is  known  to  increase  the  risk
f  developing  infection,  possibly  as  a  result  of  changes  in
ellular  immunity.17
uberculosis
uberculosis  is  one  of  the  most  prevalent  infections  world-
ide,  and  was  declared  a  global  emergency  by  the  WHO
n  1994.18,19 Approximately  2  billion  people  are  infected
ith  the  M.  tuberculosis  bacterium,  8  million  new  cases  are
eported  each  year,  and  the  disease  causes  around  2  million
eaths  annually.20
Estimates  suggest  that  between  10%  and  30%  of  TB
atients  also  present  DM,  caused  by  an  impaired  immune
esponse.21,22 In  TB  patients,  this  impairment  is  thought  to
e  caused  by  reduced  macrophage  activation,  which  dimin-
shes  the  body’s  capacity  to  destroy  the  tubercle  bacilli,
ogether  with  lower  levels  of  tumour  necrosis  factor  alpha
nd  nitric  oxide.23
Growing  evidence  of  the  association  between  these  dis-
ases  has  made  it  imperative  to  clarify  the  relationship
etween  metabolic  syndrome,  DM  and  TB.  This  will  give
nsight  into  the  different  immune  response  changes  caused
y  these  metabolic  diseases  and  shed  light  on  the  altered
ourse  of  TB.  This  will  enable  clinicians  to  take  more  a
omprehensive  therapeutic  approach  in  patients  with  these
oncomitant  pathologies,  and  reduce  mortality  by  giving
ore  appropriate  medication.
Several  studies  have  suggested  that  the  Th1-type,  and  to
 lesser  extent  the  Th17-type  immune  response,  aided  by
ytokines  such  as  IL-12,  IFN-, TNF- and  IL-17  and  IL-23,
re  the  best  defence  against  M.  tuberculosis  infection.24,25
n  the  case  of  TB  concomitant  with  DM,  the  Th1  and  Th17
esponses  are  induced  as  a  result  of  the  immunodepressive
ffect  of  diabetes,  which  in  turn  increases  immune  pathol-
gy  in  TB  infection.26A  proposed  model  for  TB  susceptibility  in  DM  is  based  on  a
efective  innate  response  in  diabetic  patients,  resulting  in  a
ritical  delay  in  priming  adaptive  immunity.  Within  the  ﬁrst
 days  following  infection,  the  phagocytic  and  chemokine
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Table  1  Comparison  of  diagnostic  criteria  for  metabolic  syndrome.
WHO  ATP  III  IDF  AHA/NHLBI
Criteria  Insulin  resistance
or diabetes,  more
than  2  criteria
Any  3  criteria Abdominal  obesity
plus  2  more
criteria
Any  3  criteria
Obesity Waist--hip  ratio
>0.90  in  men  and
0.85  in  women;  or
BMI  >30  kg/m2
Waist
circumference
>102  cm  in  men
and  >88  cm  in
women
Race-speciﬁc
waist
circumference
Waist
circumference
≥102  cm  in  men
and  ≥88  cm  in
women
Hyperglycaemia/insulin  resistance Insulin  resistance
(glucose
intolerance,
elevated  fasting
glucose,  type  2
diabetes  mellitus)
Fasting  glucose
≥100  mg/dl  or
medication
Fasting  glucose
≥100  mg/dl
Fasting  glucose
≥100  mg/dl
Dyslipidaemia  Triglycerides
≥150  mg/dl  or  LDH
<35  mg/dl  men
and  <39  mg/dl
women
Triglycerides
≥150  mg/dl  or
medication;  LDH
<40  mg/dl  men
and  <50  mg/dl
women,  or
medication
TG  ≥177  mg/dl  or
LDH  <39  mg/dl
LDH  ≥150  mg/dl  or
LDH  <40  mg/dl
men  and
<50  mg/dl  women
or  medication
Hypertension  ≥140/90  mmHg  ≥130/85  or
medication
≥140/90  mmHg  or
medication
≥130/85  or
medication
Adapted from: Gupta & Gupta. BioSci Trends 2010;4:204--212; Duvnjak & Duvnjack. J Physiol Pharmacol 2009;60: 19--24; Huang, Disease
Models Mech 2009;2:231--237.
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texpression  (particularly  CCL5  and  CCL2)  capacity  of  alveolar
macrophages  is  severely  reduced.  This  delays  macrophage,
dendritic  cell  (DC)  and  neutrophil  recruitment  on  days  5--7.
On  days  9--11,  DC  transport  to  lymph  nodes  is  delayed,  which
in  turn  delays  activation  of  TB-speciﬁc  T-lymphocytes  until
day  15  (in  a  patient  with  TB  alone,  this  would  happen  on
days  12--14).27
In  patients  with  TB  alone,  T  lymphocytes  will  have  been
transported  to  the  lung  by  day  15.  In  TB  +  DM  patients,  how-
ever,  this  is  delayed  until  day  21.  By  week  8,  an  ineffective
response  to  TB  infection,  characterised  by  IFN,  TNF and
IL1,  is  observed.27
Tuberculosis concomitant with diabetes
Diabetes  mellitus  is  known  to  be  a  risk  factor  for  infection;
however,  its  effect  on  mortality  is  less  clear.28 In  the  case
of  community-acquired  pneumonia,  the  study  published  by
Yende  et  al.  showed  higher  mortality  during  the  ﬁrst  year,
due  to  a  process  in  which  onset  of  acute  infection  wors-
ens  the  preexisting  cardiovascular  diseases  typically  found
in  diabetics.28
In  the  study  published  by  Alisjahbana  et  al.,  the  authors
conclude  that  patients  with  type  2  DM  are  at  high  risk  for
developing  active  tuberculosis.21 As  far  as  clinical  manifes-
tations  are  concerned,  patients  with  type  2  DM  present  more
symptoms  than  those  with  TB  alone.  However,  there  was  no
evidence  of  more  severe  infection  on  microbiological  culture
and  imaging  tests.21
r
v
c
TSimilarly,  Stevenson  et  al.,  in  an  analysis  of  data  for  India
ollected  by  the  WHO,  estimated  that  diabetes  accounts  for
4.8%  of  cases  of  pulmonary  TB  in  that  country.  Furthermore,
8.4%  of  TB  patients  in  India  present  concomitant  diabetes,
ven  though  the  national  prevalence  for  this  disease  is  just
.3%.  The  authors  conclude  that  the  growing  diabetes  epi-
emic  may  lead  to  a  resurgence  of  tuberculosis  in  endemic
egions.  This  has  potentially  serious  implications  for  tuber-
ulosis  control,  and  adequate  treatment  of  these  diseases
ust  become  a  priority.29
The  ﬁndings  of  the  meta-analysis  published  by  Jeon  and
urray  conﬁrm  that  risk  for  TB  is  up  to  3  times  higher  in  DM
atients  in  all  regions  worldwide.  Thus,  DM  now  presents  a
isk  comparable  with  that  of  HIV/AIDS,  since  although  the
atter  increases  the  risk  of  TB  infection  by  anything  from  2
o  9  times  compared  with  diabetes,  according  to  estimates
or  2007,  33  million  people  worldwide  suffer  from  DM.30
In  the  same  vein,  Restrepo  et  al.  found  that  patients  with
iabetes  are  up  to  8  times  more  likely  to  develop  pulmonary
B.  The  authors  attribute  the  impaired  immune  response  of
M  patients  to  hyperglycaemia,  which  is  characterised  by
levated  levels  of  IFN- caused  by  changes  in  Th1  cytokine
egulation  resulting  from  an  increase  in  advanced  glycation
nd  products  that  modify  protein  function.31
Therefore,  although  increased  cytokine  levels  would  con-
ribute  to  mycobacterial  elimination,  an  altered  immune
esponse  and  the  presence  of  dysfunctional  cytokines  pre-
ent  the  patient’s  immune  system  from  responding  to  the
hallenge.  This  could  explain  the  different  presentation  of
B  in  patients  with  and  without  DM.31
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In  their  study,  the  authors  describe  how  a  mouse  model
or  diabetes  showed  higher  bacterial  burden  and  higher
FN-  levels  in  the  advanced  stages  of  the  disease.  This
ould  also  hold  true  of  patients  with  diabetes  and  chronic
yperglycaemia,  although  they  were  unable  to  conﬁrm  the
ypothesis  due  to  the  low  sensitivity  and  speciﬁcity  of  direct
mear  tests  in  assessing  bacterial  load.31
The  study  by  Young  et  al,  in  a  sub-Saharan  population,
ound  an  altered  immune  response  in  diabetic  patients,  in
ddition  to  low  leucocyte  and  polymorphonuclear  neutrophil
evels,  and  even  a  decreased  Th1  cytokine  response  to  TB.
he  authors  go  on  to  say  that  co-presentation  with  TB  and
M  has  also  been  associated  with  more  severe  TB  symp-
oms,  such  as  increased  lung  cavitations  and  longer  periods
f  smear  positivity.32
The  most  comprehensive  analysis  of  the  relationship
etween  immune,  endocrine  and  metabolic  alterations  in
B  was  carried  out  by  Santucci  et  al.  In  this  study,  the
uthors  found  elevated  levels  of  IFN- cytokines,  IL-10,  IL-6
nd  C  reactive  protein,  cortisol,  and  the  growth  hormone,
ogether  with  reduced  levels  of  leptin,  testosterone  and
ehydroepiandrosterone  (DHEA).  Recent  studies  have  deter-
ined  that  DHEA  facilitates  the  Th1  response  and  has  a
otent  anti-inﬂammatory  effect.  Reduced  levels  of  DHEA
n  TB,  therefore,  are  associated  with  impaired  protection
gainst  tissue  damage  and  an  impaired  immune  response.20
ffects of comorbidity on treatment
o-existence  of  both  diseases  has  been  associated  with
oorer  prognosis  and  less  therapeutic  efﬁcacy.18 For  this
eason,  both  the  WHO  and  the  International  Union  Against
uberculosis  and  Lung  Disease  have  called  for  international
uidelines  on  the  management  and  control  of  tuberculosis
nd  diabetes.22
The  collaboration  between  these  organisations  resulted
n  the  Collaborative  Framework  for  Care  and  Control  of
uberculosis  and  Diabetes.  This  document  provides  the  basic
nformation  needed  to  treat  both  diseases  simultaneously
s  an  interim  measure  before  international  treatment
uidelines  can  be  drawn  up.  The  Collaborative  Framework
ecommends  that  patients  with  DM  be  monitored  for  signs
f  TB,  and  vice  versa.  It  also  recommends  the  use  of  directly
bserved  treatment  short  course  (DOTS),  which  is  suggested
o  improve  both  the  management  and  treatment  of  comor-
id  patients.33
Various  studies  have  described  the  poor  prognosis  and
herapeutic  difﬁculties  associated  with  these  comorbidities,
howing  the  obstacles  encountered  in  the  management  and
reatment  of  TB  combined  with  DM.
The  study  conducted  by  Reis-Santos  et  al.  in  a  Brazil-
an  population  found  that  treatment  failed  in  20%  of  study
atients.18 Similarly,  the  Jiménez-Corona  study  found  the
elative  risk  of  treatment  failure  in  comorbid  patients  to  be
.93  (95%  CI;  1.18--7.23),  and  the  aggregate  risk  of  failure
nd  death  to  be  1.69  (95%  CI;  1.36--2.12).  The  risk  of  relapse
r  reinfection  by  either  the  same  bacterium  or  a  different
train  in  these  patients  is  also  higher.22
Sullivan  and  Ben  Amor  found  that  developing  countries
ave  a  higher  prevalence  of  patients  with  both  TB  and  DM.
hey  go  on  to  describe  how  the  existence  of  a  systemic
C
TS.  Rodríguez-Rodríguez  et  al.
isease  added  to  the  aetiological  factors  that  affect  treat-
ent  prognosis  in  TB,  such  as  poverty,  malnutrition  and  pol-
ution,  further  complicates  the  outlook  for  these  patients.34
Both  authors  recommend  extending  the  DOTS  tuberculo-
is  strategy  to  include  diabetes  as  a  means  of  managing  both
iseases  simultaneously;  at  least  while  TB  therapy  lasts.
nce  TB  is  resolved,  they  recommend  channelling  patients
nto  speciﬁc  diabetes  management  programmes.34
uberculosis and diabetes in Mexico
easures  to  control  tuberculosis  in  Mexico  were  introduced
n  the  1930s  and  implemented  nationwide.  Nevertheless,
revalence  of  the  disease  has  increased  as  a  result  of
ncreased  immigration  and  HIV  infection.  Added  to  this,  dia-
etes  is  currently  among  the  leading  causes  of  death  in
exico,  and  estimates  suggest  that  the  disease  will  affect
1.7  million  inhabitants  by  2025.35
According  to  Jeon  and  Murray,  diabetes  triples  the  risk
f  developing  TB.  In  Mexico,  around  6%  of  the  population
uffers  from  diabetes.  More  importantly,  DM  accounts  for
early  67%  of  active  TB  cases  among  people  with  diabetes,
nd  11%  of  cases  among  the  entire  Mexican  population.30
In  the  same  vein,  the  prospective  study  published  by
iménez-Corona  in  TB  patients  in  the  south  of  Mexico  from
995  to  2010  found  that  nearly  30%  of  patients  with  TB  were
lso  affected  by  DM.  The  authors  also  found  that  social
nd  economic  differences  in  the  Mexican  population  are
he  main  obstacle  to  correct  diagnosis,  as  a  higher  socio-
conomic  level  facilitates  the  diagnosis  of  both  diseases.
his  circumstance  can  distort  the  epidemiological  data  on
exico.22
According  to  Ponce  de  Leon  et  al.,  patients  with  DM  are  6
imes  more  at  risk  of  developing  TB  than  those  without.  The
uthors  discuss  the  same  problem  reported  in  other  stud-
es,  i.e.,  socioeconomic  differences  could  hamper  access
o  health  services,  and  this  in  turn  affects  the  number  of
atients  diagnosed  with  both  diseases.36
The  authors  claim  that  DM  is  a  greater  risk  than  HIV  due  to
he  higher  prevalence  of  diabetes  revealed  by  the  Mexican
ational  Health  Survey  ENSA2000  (DM  8.18%  vs.  HIV  0.1%  in
he  over-15  age  group).  As  DM  affects  the  transmission  and
eactivation  of  TB  infection,  the  authors  recommend  correct
mplementation  of  DOTS  and  early  diagnosis.36
onclusions
he  studies  analysed  show  that  diabetes  drastically  affects
he  clinical  course  of  tuberculosis,  with  more  severe  clinical
anifestations  and  poorer  prognosis  and  treatment  efﬁcacy.
n  the  absence  of  international  guidelines  on  the  manage-
ent  and  control  of  comorbid  tuberculosis  and  diabetes,
xperts  must  establish  a  strategy  for  treating  both  diseases
imultaneously,  and  take  preventive  action  by  introducing
trategic  measures  to  prevent  comorbidity  in  developing
ountries  such  as  Mexico.onﬂict of interest
he  authors  declare  that  they  have  no  conﬂict  of  interests.
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